期刊
BLOOD
卷 113, 期 15, 页码 3604-3611出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-08-175323
关键词
-
类别
资金
- National Marrow Donor Program and the Health Resources and Services Administration [240-97-0036, 231-02-0007]
- National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung and Blood Institute [U24-CA76518]
- Office of Naval Research
- Health Resources and Services Administration (DHHS)
- AABB
- Aetna
- American Society for Blood and Marrow Transplantation
- Amgen
- Association of Medical Microbiology and Infectious Disease Canada
- Astellas Pharma US
- Baxter International
- Bayer HealthCare Pharmaceuticals
- BloodCenter of Wisconsin
- Blue Cross and Blue Shield Association
- Bone Marrow Foundation
- Canadian Blood and Marrow Transplant Group
- Celgene
- CellGenix
- Centers for Disease Control and Prevention
- ClinImmune Labs
- CTI Clinical Trial and Consulting Services
- Cubist Pharmaceuticals
- Cylex
- CytoTherm
- DOR BioPharma
- Dynal Biotech
- Invitrogen Company
- Enzon Pharmaceuticals
- European Group for Blood and Marrow Transplantation
- Gambro BCT
- Gamida Cell
- Genzyme
- Histogenetics
- HKS Medical Information Systems
- Hospira
- Infectious Diseases Society of America
- Kiadis Pharma
- Kirin Brewery
- Merck Company
- Medical College of Wisconsin
- MGI Pharma
- Michigan Community Blood Centers
- Millennium Pharmaceuticals
- Miller Pharmacal Group
- Milliman USA
- Miltenyi Biotec
- National Marrow Donor Program
- Nature Publishing Group
- New York Blood Center
- Novartis Oncology
- Oncology Nursing Society
- Osiris Therapeutics
- Otsuka Pharmaceutical Development & Commercialization
- Pall Life Sciences
- PDL BioPharma
- Pfizer
- Pharmion
- Saladax Biomedical
- Schering Plough
- Society for Healthcare Epidemiology of America
- StemCyte
- StemSoft Software
- Sysmex
- Teva Pharmaceutical Industries
- Marrow Foundation
- THERAKOS
- Vidacare
- Vion Pharmaceuticals
- ViraCor Laboratories
- ViroPharma
- Wellpoint
Limited data are available describing donor adverse events (AEs) associated with filgrastim mobilized peripheral blood stem cell (PBSC) collections in unrelated volunteers. We report results in 2408 unrelated PBSC donors prospectively evaluated by the National Marrow Donor Program (NMDP) between 1999 and 2004. Female donors had higher rates of AEs, requiring central line placement more often (17% vs 4%, P<.001), experiencing more apheresis-related AEs (20% vs 7%, P<.001), more bone pain (odds ratio [OR] = 1.49), and higher rates of grades II-IV and III-IV CALGB AEs (OR = 2.22 and 2.32). Obese donors experienced more bone pain (obese vs normal, OR = 1.73) and heavy donors had higher rates of CALGB toxicities (> 95 kg vs <70 kg, OR = 1.49). Six percent of donors experienced grade III-IV CALGB toxicities and 0.6% experienced toxicities that were considered serious and unexpected. Complete recovery is universal, however, and no late AEs attributable to donation have been identified. In conclusion, PBSC collection in unrelated donors is generally safe, but nearly all donors will experience bone pain, 1 in 4 will have significant headache, nausea, or citrate toxicity, and a small percentage will experience serious short-term adverse events. In addition, women and larger donors are at higher risk for donation-related AEs. (Blood. 2009; 113: 3604-3611)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据